| | Demographic variables | No-AKI () | AKI () | value |
| | Height (cm) | | | 0.005 | | BMI (m/kg2) | | | 0.164 | | APS III | | | <0.001 | | First wardid | 12 (8) | 14 (3) | 0.393 | | Last wardid | 14 (8) | 14 (3) | 0.968 | | Age | | | 0.126 | | Weight | | | 0.009 | | SAPS | | | <0.001 | | SOFA | | | <0.001 | | SAPS II | | | <0.001 | | Elix score | | | 0.359 | | Elixhauser vanwalraven | | | 0.169 | | Elixhauser_sid29 | | | 0.055 | | Elixhauser_sid30 | | | 0.076 | | Mingcs | 15 (1) | 15 (0) | 0.072 | | GCSmotor | 6 (2) | 6 (5) | 0.136 | | GCSverbal | 5 (5) | 1 (5) | 0.020 | | GCSeyes | 4 (1) | 3 (3) | 0.043 | | GCStotal | 14 (8) | 10 (12) | 0.057 | | Glucosemin (mmol) | | | 0.329 | | Glucosemax (mmol) | | | 0.356 | | Glucosemean (mmol) | | | 0.887 | | Glucoserange (mmol) | | | 0.167 | | HbA1c (%) | | | 0.369 | | HRfirst (bpm) | | | 0.392 | | HRmin (bpm) | | | 0.866 | | HRmax (bpm) | | | 0.002 | | CVPfirst (cmH2O) | | | 0.184 | | CVPmin (cmH2O) | | | 0.282 | | MAPfirst (mmHg) | | | 0.027 | | MAPmin (mmHg) | | | <0.001 | | MAPmax (mmHg) | | | 0.001 | | Temperaturefirst (°C) | | | 0.125 | | Temperaturemin (°C) | | | 0.057 | | Temperaturemax (°C) | | | 0.041 | | Hemoglobinfirst (g/L) | | | 0.289 | | Hemoglobinmin (g/L) | | | 0.002 | | Hemoglobinmax (g/L) | | | 0.686 | | WBCfirst (×10^9/L) | | | 0.129 | | WBCmin (×10^9/L) | | 5 | 0.073 | | WBCmax (×10^9/L) | | | 0.025 | | PLTfirst (×10^9/L) | | | 0.141 | | PLTmin (×10^9/L) | | | 0.149 | | PLTmax (×10^9/L) | | | 0.627 | | Angus sepsis, (%) | 12 (13) | 61 (19) | 0.242 | | Sedative, (%) | 44 (47) | 226 (70) | <0.001 | | Gender, (%) | 55 (59) | 231 (71) | 0.036 | | SIRS, (%) | | | 0.016 | | Ventilation, (%) | 47 (51) | 244 (75) | <0.001 | | Vasoactive drugs, (%) | 37 (40) | 196 (60) | <0.001 | | Congestive heart failure, (%) | 3 (3) | 16 (5) | 0.586 | | Cardiac arrhythmias, (%) | 5 (5) | 23 (7) | 0.726 | | Valvular disease, (%) | 1 (1) | 8 (2) | 0.691 | | Pulmonary circulation, (%) | 2 (2) | 3 (1) | 0.310 | | Peripheral vascular, (%) | 12 (13) | 40 (12) | 1.000 | | Hypertension, (%) | 5 (5) | 43 (13) | 0.055 | | Paralysis, (%) | 4 (4) | 6 (2) | 0.240 | | Other neurological, (%) | 3 (3) | 16 (5) | 0.586 | | Chronic pulmonary, (%) | 11 (12) | 50 (15) | 0.484 | | Diabetes uncomplicated, (%) | 20 (22) | 95 (29) | 0.175 | | Diabetes complicated, (%) | 2 (2) | 14 (4) | 0.541 | | Diabetes all, (%) | 22 (24) | 109 (34) | 0.089 | | Furosemide, (%) | 11 (12) | 37 (11) | 1.000 | | CHF, (%) | 22 (24) | 108 (33) | 0.099 | | Atrial fibrillation, (%) | 21 (23) | 120 (37) | 0.013 | | Renal disease, (%) | 7 (8) | 35 (11) | 0.466 | | Liver disease, (%) | 1 (1) | 8 (2) | 0.691 | | COPD, (%) | 5 (5) | 31 (10) | 0.289 | | CAD, (%) | 50 (54) | 199 (61) | 0.227 | | Stroke, (%) | 8 (9) | 24 (7) | 0.872 | | Malignancy, (%) | 8 (9) | 32 (10) | 0.866 | | Cardiopulmonary bypass, (%) | 31 (33) | 193 (60) | <0.001 | | CABG, (%) | 17 (18) | 151 (47) | <0.001 | | Left heart catheterization, (%) | 36 (39) | 121 (37) | 0.906 |
|
|